Biochemical and imaging surveillance in Li-Fraumeni syndrome - Authors' reply

Affiliations

¹ The Hospital for Sick Children, University of Toronto, Toronto, M5G 1X8, Canada.
² The Hospital for Sick Children, University of Toronto, Toronto, M5G 1X8, Canada. Electronic address: david.malkin@sickkids.ca.

Comment

Anita Villani et al. Lancet Oncol. 2016 Nov.

. 2016 Nov;17(11):e473.

doi: 10.1016/S1470-2045(16)30525-3.

¹ The Hospital for Sick Children, University of Toronto, Toronto, M5G 1X8, Canada.
² The Hospital for Sick Children, University of Toronto, Toronto, M5G 1X8, Canada. Electronic address: david.malkin@sickkids.ca.

No abstract available

Comment on

Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.
Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, Novokmet A, Finlay J, Malkin D. Villani A, et al. Lancet Oncol. 2011 Jun;12(6):559-67. doi: 10.1016/S1470-2045(11)70119-X. Epub 2011 May 19. Lancet Oncol. 2011. PMID: 21601526
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H, Gallinger B, Naumer A, Kohlmann W, Novokmet A, Tabori U, Tijerin M, Greer ML, Finlay JL, Schiffman JD, Malkin D. Villani A, et al. Lancet Oncol. 2016 Sep;17(9):1295-305. doi: 10.1016/S1470-2045(16)30249-2. Epub 2016 Aug 5. Lancet Oncol. 2016. PMID: 27501770
Biochemical and imaging surveillance in Li-Fraumeni syndrome.
Raskind WH, Hisama FM, Bennett RL. Raskind WH, et al. Lancet Oncol. 2016 Nov;17(11):e472. doi: 10.1016/S1470-2045(16)30530-7. Lancet Oncol. 2016. PMID: 27819239 No abstract available.